Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE:OXB), (“the Company”) the leading gene and cell therapy based biopharmaceutical company, today announces that results from the 21 patients in its Phase I study of RetinoStat… Read More
Oxford, UK – 5 May 2015: Oxford BioMedica plc (LSE:OXB) (“the Group”), a leading gene and cell therapy group, today announces that Professor Stéphane Palfi MD, PhD has presented a summary of the results from the 12 months and long… Read More
Oxford, UK – 1 May 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford BioMedica” or the “Group”) a leading gene and cell therapy Group, today announces that it has secured a $50 million loan facility from a subsidiary of Oberland… Read More
London, UK – 2 April 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, gives notice that copies of the 2014 Annual Report and Accounts and the Notice of Annual… Read More
London, UK – 20 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that Dr Paul Blake, Chief Development Officer, will present at the 3… Read More
You have selected Encore.Encore is InterCall’s recording replay service and provides the opportunity to listen to the Event for those who were unable to attend it live or who would like to listen… Read More
Oxford, UK – 13 March 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy group, today announces its preliminary results for the twelve months ended 31 December 2014. Read More
Results date: – 13 March 2015: Oxford, UK – 6 March 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Company”) a leading gene and… Read More
Oxford, UK – 5 March 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Company”) a leading gene and cell therapy company, announces that Tim Watts, Chief Financial Officer, will present a company overview on 9 March 2015… Read More
London, UK – 3 March 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, announces that John Dawson, Chief Executive Officer, and Tim Watts, Chief Financial Officer, will participate in… Read More
Oxford, UK – 23 February 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Company”) a leading gene and cell therapy company, today welcomed the Rt Hon Danny Alexander, Chief Secretary to the Treasury, to its laboratories on the Oxford… Read More
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present… Read More